trial · primary record
Belantamab mafodotin
Amyloidosis
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2033-01-12 |
| Primary endpoint | Overall complete hematologic response (CHR) rate |
| Registry ID | NCT07224672 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:39.659Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07224672
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.